This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Acasti Pharma Future Growth
Future criteria checks 4/6
Key information
-28.1%
Earnings growth rate
-30.2%
EPS growth rate
| Pharmaceuticals earnings growth | 58.2% |
| Revenue growth rate | 26.1% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 16 Feb 2023 |
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2025 | 97 | -38 | 27 | N/A | 3 |
| 3/31/2024 | 160 | 161 | 12 | -25 | 2 |
| 3/31/2023 | N/A | -6 | -17 | -17 | 2 |
| 12/31/2022 | N/A | -17 | -16 | -16 | N/A |
| 9/30/2022 | N/A | -17 | -17 | -17 | N/A |
| 6/30/2022 | N/A | -11 | -19 | -19 | N/A |
| 3/31/2022 | N/A | -10 | -17 | -17 | N/A |
| 12/31/2021 | 0 | -12 | -16 | -16 | N/A |
| 9/30/2021 | 0 | -11 | -15 | -15 | N/A |
| 6/30/2021 | 0 | -18 | -14 | -14 | N/A |
| 3/31/2021 | 0 | -20 | -14 | -14 | N/A |
| 12/31/2020 | 0 | 3 | -16 | -15 | N/A |
| 9/30/2020 | N/A | -6 | -19 | -18 | N/A |
| 6/30/2020 | N/A | -21 | -21 | -20 | N/A |
| 3/31/2020 | N/A | -26 | -23 | -23 | N/A |
| 12/31/2019 | N/A | -56 | -29 | -29 | N/A |
| 9/30/2019 | N/A | -46 | -29 | -29 | N/A |
| 6/30/2019 | N/A | -42 | -27 | -27 | N/A |
| 3/31/2019 | N/A | -39 | -25 | -25 | N/A |
| 12/31/2018 | N/A | -31 | -20 | -19 | N/A |
| 9/30/2018 | N/A | -34 | -17 | -16 | N/A |
| 6/30/2018 | N/A | -20 | -13 | -13 | N/A |
| 3/31/2018 | N/A | -17 | -10 | -10 | N/A |
| 3/31/2017 | N/A | -8 | -7 | -5 | N/A |
| 11/30/2016 | 0 | -7 | N/A | -5 | N/A |
| 8/31/2016 | 0 | -7 | N/A | -5 | N/A |
| 5/31/2016 | 0 | -6 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACST's earnings are forecast to decline over the next 3 years (-28.1% per year).
Earnings vs Market: ACST is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ACST is expected to become profitable in the next 3 years.
Revenue vs Market: ACST's revenue (26.1% per year) is forecast to grow faster than the Canadian market (5.5% per year).
High Growth Revenue: ACST's revenue (26.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACST's Return on Equity is forecast to be high in 3 years time